Advertisement

Annals of Surgical Oncology

, Volume 25, Supplement 3, pp 810–811 | Cite as

ASO Author Reflections: Neoadjuvant Therapy Versus Upfront Resection for Pancreatic Cancer

  • Stefano Andrianello
  • Giovanni Marchegiani
  • Roberto SalviaEmail author
ASO Author Reflections

Notes

Disclosure

The authors have no conflicts of interest to disclose.

References

  1. 1.
    Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2013;364(19):1817–25.CrossRefGoogle Scholar
  2. 2.
    Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703.CrossRefGoogle Scholar
  3. 3.
    Lim KH, Chung E, Khan A, et al. Neoadjuvant therapy of pancreatic cancer: the emerging paradigm? Oncologist. 2012;17(2):192–200.CrossRefGoogle Scholar
  4. 4.
    Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015;261(1):12–7.CrossRefGoogle Scholar
  5. 5.
    Marchegiani G, Andrianello S, Nessi C, et al. Neoadjuvant therapy versus upfront resection for pancreatic cancer: the actual spectrum and clinical burden of postoperative complications. Ann Surg Oncol. 2018; 25(3):626–37.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Stefano Andrianello
    • 1
  • Giovanni Marchegiani
    • 1
  • Roberto Salvia
    • 1
    Email author
  1. 1.Department of General and Pancreatic Surgery, The Pancreas InstituteUniversity of Verona Hospital TrustVeronaItaly

Personalised recommendations